Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive geno- and phenotyping to reduce 5-FU/capecitabine toxicity
2019-004003-12Phase 4Completed
- Sponsor
- Jessa Hospital
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fluorouracil and capecitabine in gastric cancer (GC), pancreatic cancer (PC), colon cancer and 3 more (2 arms), sponsored by Jessa Hospital. Primary endpoint: Toxicity. Started Dec 2019; status: completed.
02
Drugs
fluorouracilcapecitabine
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)colon cancerrectal canceranal cancer
Beyond the preview
Go deeper on 2019-004003-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004003-12.